MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a Phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments

INTRODUCTION: The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of the humanized anti-CD4 monoclonal antibody MTRX1011A in a randomized, double-blind placebo-controlled Phase 1 study in patients with rheumatoid arthritis (RA). METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Scheerens, Heleen, Su, Zheng, Irving, Bryan, Townsend, Michael J, Zheng, Yanan, Stefanich, Eric, Chindalore, Vishala, Bingham, Clifton O, Davis, John C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308112/
https://www.ncbi.nlm.nih.gov/pubmed/22029963
http://dx.doi.org/10.1186/ar3502

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308112/
https://www.ncbi.nlm.nih.gov/pubmed/22029963
http://dx.doi.org/10.1186/ar3502

Ejemplares similares